In their recent article, McDougle et al1
concluded that patients with obsessive-compulsive disorder (OCD) refractory
to serotonin reuptake inhibitor (SRI) monotherapy may respond to a mean ±
SD low dose of risperidone (2.2 ± 0.7 mg) added to SRI treatment. However,
the observed relationship between low doses of risperidone and its antiobsessional
effect needs further evaluation.